Minnesota Agencies

The task force shall:

(1) survey existing studies in the scientific literature on the therapeutic efficacy of psychedelic medicine in the treatment of mental health conditions, including depression, anxiety, post-traumatic stress disorder, bipolar disorder, and any other mental health conditions and medical conditions for which a psychedelic medicine may provide an effective treatment option;

(2) compare the efficacy of psychedelic medicine in treating the conditions described in clause (1) with the efficacy of treatments currently used for these conditions; and

(3) develop a comprehensive plan that covers:

• statutory changes necessary for the legalization of psychedelic medicine;
• state and local regulation of psychedelic medicine;
• federal law, policy, and regulation of psychedelic medicine, with a focus on retaining state autonomy to act without conflicting with federal law, including methods to resolve conflicts such as seeking an administrative exemption to the federal Controlled Substances Act under United States Code, title 21, section 822(d), and Code of Federal Regulations, title 21, part 1307.03; seeking a judicially created exemption to the federal Controlled Substances Act; petitioning the United States Attorney General to establish a research program under United States Code, title 21, section 872(e); using the Food and Drug Administration's expanded access program; and using authority under the federal Right to Try Act; and
• education of the public on recommendations made to the legislature and others about necessary and appropriate actions related to the legalization of psychedelic medicine in the state.

The task force shall submit two reports to the chairs and ranking minority members of the legislative committees with jurisdiction over health and human services that detail the task force's findings regarding the legalization of psychedelic medicine in the state, including the comprehensive plan. The first report must be submitted by February 1, 2024, and the second report must be submitted by January 1, 2025.

The Psychedelic Medicine Task Force is established to advise the legislature on the legal, medical, and policy issues associated with the legalization of psychedelic medicine in the state. For purposes of this section, "psychedelic medicine" means 3,4-methylenedioxymethamphetamine (MDMA), psilocybin, and LSD.

Members shall be designated or appointed to the task force by July 15, 2023. The first meeting of the task force shall occur by August 1, 2023.

The first report submitted by the task force describes the task force duties and charge from the Minnesota Legislature, the formation of the task force, early meetings, and the work that the task force plans to do in 2024. The task force submitted their final report to the Legislature in January 2025.

The Psychedelic Medicine Task Force consists of 23 members, including:

• the governor or a designee;
• two members of the house of representatives, one appointed by the speaker of the house and one appointed by the minority leader of the house of representatives, and two members of the senate, one appointed by the senate majority leader and one appointed by the senate minority leader;
• the commissioner of health or a designee;
• the commissioner of public safety or a designee;
• the commissioner of human services or a designee;
• the attorney general or a designee;
• the executive director of the Board of Pharmacy or a designee;
• the commissioner of commerce or a designee; and
• members of the public, appointed by the governor, who have relevant knowledge and expertise, including:
  • two members representing Indian Tribes within the boundaries of Minnesota, one representing the Ojibwe Tribes and one representing the Dakota Tribes;
  • one member with expertise in the treatment of substance use disorders;
  • one member with experience working in public health policy;
  • two veterans with treatment-resistant mental health conditions;
  • two patients with treatment-resistant mental health conditions;
  • one psychiatrist with experience treating treatment-resistant mental health conditions, including post-traumatic stress disorder;
  • one health care practitioner with experience in integrative medicine;
  • one psychologist with experience treating treatment-resistant mental health conditions, including post-traumatic stress disorder; and
  • one member with demonstrable experience in the medical use of psychedelic medicine.